Skip to main
  1. Stocks
  2. Shattuck Labs
  3. Forecast
STTK

Shattuck Labs (STTK) Stock Forecast & Price Target

Shattuck Labs (STTK) Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Shattuck Labs is attractive because its lead DR3 antagonist SL-325 has generated strong Phase 1 healthy-volunteer evidence of durable receptor occupancy, a 3.7% ADA rate, and clean safety, which materially de-risks a mechanism that has been hindered by immunogenicity in TL1A-directed peers. The planned Phase 2 RECEPTIVE-CD1 Crohn’s study in 3Q26, the HS expansion later this year, and the SL-846 bispecific and SL-425 programs broaden the pipeline and create multiple shots on goal around a differentiated receptor-focused strategy. Financially, the company ended 2Q26 with $208.3 million in cash, and management expects that to fund operations into 2029, supporting execution without near-term balance-sheet pressure.

Bears say

Shattuck Labs is a high-risk biotech story whose preclinical assets may never advance into clinical studies, leaving SL-325 and related DR3 programs without a clear path to value creation. The competitive backdrop is unfavorable because TL1A has attracted large pharma and multiple biotechs, while established therapies for UC and Crohn’s already exist, forcing Shattuck to prove clear differentiation and eventually build costly commercial infrastructure. Financially, profitability is not expected for several years, and the company will likely need additional capital to fund long development timelines, with no assurance that financing will be available on favorable terms or that its intellectual property will be fully protected.

Shattuck Labs (STTK) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Shattuck Labs and is not a guaranteed prediction by Public.com or investment advice.

Shattuck Labs (STTK) Analyst Forecast & Price Prediction

Get the latest Shattuck Labs (STTK) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Shattuck Labs (STTK)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Shattuck Labs (STTK) Forecast

Analysts have given Shattuck Labs (STTK) a Strong Buy based on their latest research and market trends.

According to 9 analysts, Shattuck Labs (STTK) has a Strong Buy consensus rating as of Nov 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Shattuck Labs (STTK)


Shattuck Labs (STTK) Analyst Forecast & Price Prediction

Get the latest Shattuck Labs (STTK) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Shattuck Labs (STTK)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover STTK stock data and trends